Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982203 | PMC |
| http://dx.doi.org/10.1016/j.jaccao.2022.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps.
Br J Hosp Med (Lond)
January 2025
Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.
The burdens of cardiovascular (CV) diseases and cardiotoxic side effects of cancer treatment in oncology patients are increasing in parallel. The European Society of Cardiology (ESC) 2022 Cardio-Oncology guidelines recommend the use of standardized risk stratification tools to determine the risk of cardiotoxicity associated with different anticancer treatment modalities and the severity of their complications. The use of the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) is essential for assessing risk prior to starting cancer treatment, and validation of these methods has been performed in patients receiving anthracyclines, human epidermal receptor 2 (HER2)-targeted therapies and breakpoint cluster region-abelson oncogene locus (BCR-ABL) inhibitors.
View Article and Find Full Text PDFCardiovascular health in breast cancer patients: insight on BRCA1/2 mutations impact.
Cardiooncology
January 2025
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
Background: Breast cancer (BC) and cardiovascular disease (CVD) are prevalent comorbidities in aging populations. Advances in BC treatment have improved survival rates but increased the risk of CVD, particularly among younger patients with BRCA1/2 mutations. BRCA1/2 gene mutations, prevalent in younger BC patients, impair cardioprotective effects, elevating CVD risk alongside cancer treatments.
View Article and Find Full Text PDFCardiovascular Risk in Prostate Cancer: State-of-the-Art Review.
JACC CardioOncol
December 2024
Division of Urology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation.
View Article and Find Full Text PDFCardiovascular Considerations During Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
JACC CardioOncol
December 2024
Duke Cancer Institute, Department of Medicine, Duke University, Durham, North Carolina, USA.
The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification, and management. This expert panel summarizes the consensus of opinions of diverse health care professionals in several key areas: 1) cardioprotection involves strategies aimed at the primary prevention of cancer therapy-related cardiovascular toxicity; 2) surveillance entails monitoring for cancer therapy-related cardiovascular toxicity during cancer therapy; 3) permissive cardiotoxicity is the informed continuation of cancer therapy in the presence of cardiovascular toxicity, along with the implementation of mitigating cardiovascular treatments; and 4) special considerations include the invasive management of severe cardiovascular disease in patients receiving treatments for advanced cancer and the exploration of drug-drug interactions in cardio-oncology.
View Article and Find Full Text PDFAssessment of cardio-oncology knowledge and practice among healthcare providers in Saudi Arabia: a comprehensive nationwide survey.
Cardiooncology
December 2024
Department of Medical Oncology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Introduction: The evolving field of oncology necessitates effective management of cancer-related cardiovascular diseases. In Saudi Arabia, the incidence of cancer is rising, and there is a critical need for cardio-oncology services to address cancer treatment-related cardiovascular toxicity. This study aimed to evaluate the knowledge and practices of healthcare providers (HCPs) in Saudi Arabia regarding cardio-oncology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!